Alexander C Huang

List of Publications by Year
in descending order

33 papers	11,493 citations	279798 23 h-index	434195 31 g-index
37 all docs	37 docs citations	37 times ranked	21637 citing authors

#	Article	IF	Citations
1	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 2018, 560, 382-386.	27.8	1,836
2	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	27.8	1,280
3	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 2020, 369, .	12.6	1,280
4	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 563-571.	30.7	1,150
5	Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science, 2016, 354, 1160-1165.	12.6	939
6	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 2019, 571, 211-218.	27.8	934
7	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12.	28.9	830
8	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity, 2020, 52, 825-841.e8.	14.3	497
9	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	30.7	466
10	TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8ÂT Cell-Fate Decision. Immunity, 2019, 51, 840-855.e5.	14.3	409
11	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	30.7	365
12	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
13	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nature Immunology, 2022, 23, 660-670.	14.5	191
14	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Internal Medicine, 2021, 181, 195.	5.1	168
15	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. Science Immunology, 2021, 6, .	11.9	152
16	Non-conventional Inhibitory CD4+Foxp3â^'PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell, 2018, 33, 1017-1032.e7.	16.8	112
17	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	12.8	107
18	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer, 2018, 119, 1200-1207.	6.4	83

#	Article	IF	Citations
19	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. Journal of the National Cancer Institute, 2021, 113, 162-170.	6.3	81
20	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 TÂcells. Cell Reports, 2021, 35, 109120.	6.4	60
21	Human epigenetic and transcriptional TÂcell differentiation atlas for identifying functional TÂcell-specific enhancers. Immunity, 2022, 55, 557-574.e7.	14.3	47
22	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma. Clinical Cancer Research, 2022, 28, 1098-1106.	7.0	32
23	Rates of COVID-19â€“Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa120.	2.9	26
24	Signaling Through FcÎ³RIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. Frontiers in Immunology, 2022, 13, 834988.	4.8	26
25	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	3.3	25
26	Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 TÂcell responses. Cancer Cell, 2022, 40, 738-753.e5.	16.8	19
27	Postvaccination graft dysfunction/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes. Blood Advances, 2020, 4, 1378-1382.	5.2	16
28	Dichotomous and stable gamma delta T-cell number and function in healthy individuals. , 2021, 9, e002274.		13
29	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Annals of Surgical Oncology, 2020, 27, 2915-2926.	1.5	11
30	Alpha-Fetoprotein-Producing Lung Hepatoid Adenocarcinoma with Brain Metastasis Treated with S-1. Case Reports in Oncology, 2021, 13, 1552-1559.	0.7	9
31	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncology Practice, 2021, 17, e1879-e1886.	2.9	2
32	Abstract PO068: Distinct immune signatures predicting clinical response to PD-1 blockade therapy in gynecological cancers revealed by high-dimensional immune profiling. , 2021, , .		0
33	Abstract 3579: T cell intrinsic DNA damage and repair response as a novel marker associated with clinical response to PD-1 blockade. Cancer Research, 2022, 82, 3579-3579.	0.9	0